MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026
PR Newswire•16/11/2026•08:31 ET
0
Key Highlights
- ➤DA-1726 cut glucose 43.0% and 39.2% versus retatrutide’s 21.5% and 32.5%
- ➤DA-1726 delivered 34.2% and 41.7% weight loss, comparable to retatrutide
- ➤DA-1726 reduced food intake 19.6% and 31.2%, below retatrutide’s 36.7% and 41.4%
- ➤DA-1726 increased hepatic and circulating FGF21, with statistically significant results
- ➤Phase 2 MetALD and ALD study targeted to begin in second half of 2027
Expert Statements
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“Given our focus on liver-related metabolic disease, we are particularly encouraged that DA-1726 increased both gene expression and protein levels of hepatic Fgf21, a key hormone in the regulation of lipid and carbohydrate metabolism.”
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“Greater glucose lowering and weight loss comparable to retatrutide, despite less suppression of food intake, further support DA-1726's differentiated metabolic profile.”
Hyung Heon Kim, President and Chief Executive Officer of MetaVia
“Together with our recent clinical data demonstrating substantial reductions in liver fat and body weight, these findings strengthen the rationale for advancing DA-1726 into a Phase 2 study in MetALD and ALD, targeted to begin in the second half of 2027.”
MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026 PR Newswire
Statistically Significant Increase in Liver and Circulating FGF21 Expression
Get started
Create a free account to read the full story.
